Newsfeeds Archive - Page 3 of 3

1 minute read

Can-Fite BioPharma To Present Liver Cancer Data At Upcoming Conferences

December 28, 8:05 AM

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today provided an update on

CANF

25 minute read

Options

Stocks That Hit 52-Week Lows On Friday

By Benzinga Insights

October 21, 1:26 PM

On Friday morning, 446 companies hit new 52-week lows.

ABG

1 minute read

Can-Fite Reports New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented By KOL Dr. Papp At The 31st European Academy Of Dermatology

By Benzinga Newsdesk

September 12, 7:02 AM

Dr. Papp: "The safety results on Piclidenoson and its progressive effectiveness over the study period position it as unique among the current treatment options especially given the chronic nature of psoriasis

CANF

2 minute read

Can-Fite Announces Piclidenoson Is Set To Enter Clinical Trial For Treatment Of Osteoarthritis In Dogs Efficacy Trial To Commence And Financially Covered By Vetbiolix

By Bill Haddad

August 17, 7:27 AM

Safety study successfully completed; efficacy trial to commence and financially covered by Vetbiolix Canine osteoarthritis market is projected to reach $3 billion by 2028 PETACH TIKVA, Israel--(BUSINESS WIRE)--

CANF

6 minute read

Boeing, PriceSmart And 80 Biggest Movers From Yesterday

By Lisa Levin

July 13, 4:59 AM

Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.

AAL

6 minute read

Alibaba, Zoom Video And 76 Biggest Movers From Yesterday

By Lisa Levin

July 12, 5:35 AM

Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.

ADTX

2 minute read

Can-Fite To Submit FDA & EMA Registration Plans For Piclidenoson In The Oral Treatment Of Moderate To Severe Psoriasis

By Bill Haddad

July 11, 7:02 AM

Further analysis of Phase III COMFORT™ data show Piclidenoson's superior safety profile and higher patient compliance compared to Otezla® Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CFBI), a

CANF

5 minute read

Akerna Shares Dip 53%, Here’s 78 Biggest Movers From Yesterday

By Lisa Levin

July 1, 4:52 AM

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.

ADSE